Download PDF
Am J Perinatol 2022; 39(05): 554-561
DOI: 10.1055/s-0040-1717075
Original Article

Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy

Taylor S. Freret
1   Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts
,
Pedro Exman
2   Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
3   Department of Medical Oncology, Centro Paulista de Oncologia, Grupo Oncoclinicas, Sao Paulo, Brazil
,
Erica L. Mayer
2   Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
,
Sarah E. Little
1   Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts
,
Katherine E. Economy
1   Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Objective Breast cancer is one of the most frequently diagnosed cancers in pregnancy and is commonly treated with chemotherapy. To date, studies examining effects of chemotherapy during pregnancy on fetal growth have yielded conflicting results, and most are limited by small sample sizes or are nonspecific with respect to cytotoxic regimen or type of cancer treated. We sought to evaluate the effect of chemotherapy for breast cancer in pregnancy on birthweight and small for gestational age infants.

Study Design This is a retrospective cohort study of 74 women diagnosed with pathologically confirmed breast cancer during pregnancy between 1997 and 2018 at one of three academic medical centers, who had a singleton birth with known birthweight. Forty-nine received chemotherapy and 25 did not receive chemotherapy. Linear regression modeling was used to compare birthweight (by gestational age and sex-specific z-score) by chemotherapy exposure. Subanalyses of specific chemotherapy regimen and duration of chemotherapy exposure were also performed. Placental, neonatal, and maternal outcomes were also analyzed by chemotherapy exposure.

Results In the adjusted model, chemotherapy exposure was associated with lower birthweight (Δ z-score = −0.49, p = 0.03), but similar rates of small for gestational age (defined as birthweight <10th percentile for gestational age) infants (8.2 vs. 8.0%, p = 1.0; Fisher's exact test). Each additional week of chemotherapy (Δ z-score = −0.05, p = 0.03) was associated with decreased birthweight, although no association was found with specific chemotherapy regimen. Chemotherapy exposure was associated with lower median placental weight percentile by gestational age (9th vs. 75th, p < 0.05). Secondary maternal outcomes were similar between the group that did and did not receive chemotherapy.

Conclusion Chemotherapy for breast cancer in pregnancy in this cohort is associated with lower birthweight but no difference in the rate of small for gestational age infants.

Key Points

  • Chemotherapy for breast cancer in pregnancy is associated with decreased birthweight but similar rates of small for gestational age infants.

  • Birthweight did not differ according to chemotherapy regimen.

  • There is no difference in the rate of small for gestational age infants.

Keywords

breast cancer - chemotherapy in pregnancy - fetal growth - birthweight

Note

This study was presented as a poster at the 39th Society for Maternal–Fetal Medicine Annual Meeting, in Las Vegas, NV, in February 15, 2019.




Publication History

Received: 23 January 2020

Accepted: 22 August 2020

Article published online:
24 September 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Salani R, Billingsley CC, Crafton SM. Cancer and pregnancy: an overview for obstetricians and gynecologists. Am J Obstet Gynecol 2014; 211 (01) 7-14
    CrossrefPubMedGoogle Scholar
  • 2 Meisel JL, Economy KE, Calvillo KZ. et al. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus 2013; 2 (01) 297
    CrossrefPubMedGoogle Scholar
  • 3 Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010; 16 (01) 76-82
    CrossrefPubMedGoogle Scholar
  • 4 Pavlidis N, Pentheroudakis G. The pregnant mother with breast cancer: diagnostic and therapeutic management. Cancer Treat Rev 2005; 31 (06) 439-447
    CrossrefPubMedGoogle Scholar
  • 5 Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet 2012; 379 (9815): 570-579
    CrossrefPubMedGoogle Scholar
  • 6 Hahn KM, Johnson PH, Gordon N. et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107 (06) 1219-1226
    CrossrefPubMedGoogle Scholar
  • 7 Loibl S, Han SN, von Minckwitz G. et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012; 13 (09) 887-896
    CrossrefPubMedGoogle Scholar
  • 8 Abdalla N, Bizoń M, Piórkowski R, Stanirowski P, Cendrowski K, Sawicki W. Does chemotherapy for gynecological malignancies during pregnancy cause fetal growth restriction?. BioMed Res Int 2017; 2017: 7543421
    CrossrefPubMedGoogle Scholar
  • 9 Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23 (18) 4192-4197
    CrossrefPubMedGoogle Scholar
  • 10 Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 2010; 33 (03) 221-228
    CrossrefPubMedGoogle Scholar
  • 11 Van Calsteren K, Heyns L, De Smet F. et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010; 28 (04) 683-689
    CrossrefPubMedGoogle Scholar
  • 12 de Haan J, Verheecke M, Van Calsteren K. International Network on Cancer and Infertility Pregnancy (INCIP). et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol 2018; 19 (03) 337-346
    CrossrefPubMedGoogle Scholar
  • 13 Chou JH, Roumiantsev S, Singh R. PediTools Electronic Growth Chart Calculators: Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res 2020; 22 (01) e16204
    CrossrefPubMedGoogle Scholar
  • 14 Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125 (02) e214-e224
    CrossrefPubMedGoogle Scholar
  • 15 Inoue S, Naruse H, Yorifuji T. et al. Impact of maternal and paternal smoking on birth outcomes. J Public Health (Oxf) 2017; 39 (03) 1-10
    CrossrefPubMedGoogle Scholar
  • 16 Hung TH, Hsieh TT, Chen SF. Risk of abnormal fetal growth in women with early- and late-onset preeclampsia. Pregnancy Hypertens 2018; 12: 201-206
    CrossrefPubMedGoogle Scholar
  • 17 Pinar H, Sung CJ, Oyer CE, Singer DB. Reference values for singleton and twin placental weights. Pediatr Pathol Lab Med 1996; 16 (06) 901-907
    CrossrefPubMedGoogle Scholar
  • 18 Garofalo S, Degennaro VA, Salvi S. et al. Perinatal outcome in pregnant women with cancer: are there any effects of chemotherapy?. Eur J Cancer Care (Engl) 2017;26(06):
    PubMedGoogle Scholar
  • 19 Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 1992; 152 (03) 573-576
    CrossrefPubMedGoogle Scholar
  • 20 Maggen C, Wolters VERA, Cardonick E. International Network on Cancer, Infertility and Pregnancy (INCIP). et al. Pregnancy and cancer: the INCIP project. Curr Oncol Rep 2020; 22 (02) 17
    CrossrefPubMedGoogle Scholar
  • 21 Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol 2012; 23 (12) 3016-3023
    CrossrefPubMedGoogle Scholar
  • 22 Exman P, Freret T, Economy K. et al. Abstract P1–17–02: Outcomes and safety of paclitaxel and granulocyte-colony stimulating factor (GCSF) in breast cancer in pregnancy (BCP)—a multi-institutional retrospective analysis. Cancer Res 2019; 79 (04) 1-17
    PubMedGoogle Scholar
  • 23 Toledo MT, Ventrucci G, Marcondes MC. Cancer during pregnancy alters the activity of rat placenta and enhances the expression of cleaved PARP, cytochrome-c and caspase 3. BMC Cancer 2006; 6: 168
    CrossrefPubMedGoogle Scholar
  • 24 Verheecke M, Cortès Calabuig A, Finalet Ferreiro J. et al. Genetic and microscopic assessment of the human chemotherapy-exposed placenta reveals possible pathways contributive to fetal growth restriction. Placenta 2018; 64: 61-70
    CrossrefPubMedGoogle Scholar
  • 25 Cardonick E, Eicheldinger E, Gaughan J. Chemotherapy is avoided during the first trimester of pregnancy, when is the safest time to start treatment during the second or third trimester?. Pro Clin Gynecol Obstet 2019; 2 (01) 1005
    PubMedGoogle Scholar
  • 26 Maternal Cancer Diagnosis and Treatment During Pregnancy: A Database for Maternal, Fetal, and Neonatal Outcomes (CANCRPREGREG). Accessed January, 2016 at: https://clinicaltrialsgov/ct2/show/NCT02749474
    PubMedGoogle Scholar
  • 27 Mir O, Berveiller P, Goffinet F. et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010; 21 (02) 425-426
    CrossrefPubMedGoogle Scholar